

DAFTAR PUSTAKA

- Abdellatif, K.R., Abdelall, E.K., Elshemy, H.A., Philoppes, J.N., Hassanein, E.H. and Kahk, N.M., 2022, Design, synthesis, and pharmacological evaluation of novel and selective COX-2 inhibitors based on celecoxib scaffold supported with in vivo anti-inflammatory activity, ulcerogenic liability, ADME profiling and docking study, *Bioorg. Chem.*, 120, 105627.
- Ahmadi, M., Bekeschus, S., Weltmann, K.D., von Woedtke, T. and Wende, K., 2022, Non-steroidal anti-inflammatory drugs: Recent advances in the use of synthetic COX-2 inhibitors, *RSC Med. Chem.*, 13(5), 471-496.
- Alanazi, A.M., El-Azab, A.S., Al-Suwaidan, I.A., ElTahir, K.E.H., Asiri, Y.A., Abdel-Aziz, N.I. and Alaa, A.M., 2015, Structure-based design of phthalimide derivatives as potential cyclooxygenase-2 (COX-2) inhibitors: anti-inflammatory and analgesic activities, *Eur. J. Med. Chem.*, 92, 115-123.
- Bell, E.W. and Zhang, Y., 2019, DockRMSD: an open-source tool for atom mapping and RMSD calculation of symmetric molecules through graph isomorphism, *J. Cheminform.*, 11, 1-9.
- Boittier, E.D., Tang, Y.Y., Buckley, M.E., Schuurs, Z.P., Richard, D.J. and Gandhi, N.S., 2020, Assessing molecular docking tools to guide targeted drug discovery of CD38 inhibitors, *Int. J. Mol. Sci.*, 21(15), 5183.
- Chen, G., Seukep, A.J. and Guo, M., 2020, Recent advances in molecular docking for the research and discovery of potential marine drugs, *Mar. Drugs*, 18(11), 545.
- Christensen, A.S., Kubar, T., Cui, Q. and Elstner, M., 2016, Semiempirical quantum mechanical methods for noncovalent interactions for chemical and biochemical applications, *Chem. Rev.*, 116(9), 5301-5337.
- Durrant, J.D. and McCammon, J.A., 2011, Molecular dynamics simulations and drug discovery, *BMC Biol.*, 9, 1-9.
- Eberhardt, J., Santos-Martins, D., Tillack, A.F. and Forli, S., 2021, AutoDock Vina 1.2.0: New docking methods, expanded force field, and python bindings, *J. Chem. Inf. Model.*, 61(8), 3891-3898.
- Fadlan, A. and Nusantara, Y.R., 2021, The effect of energy minimization on the molecular docking of acetone-based oxindole derivatives, *JKPK (Jurnal Kimia dan Pendidikan Kimia)*, 6(1), 69-77.
- Faki, Y. and Er, A., 2021, Different chemical structures and physiological/pathological roles of cyclooxygenases, *Rambam Maimonides Med. J.*, 12(1).
- Fan, J., Fu, A. and Zhang, L., 2019, Progress in molecular docking, *Quant. Biol.*, 7, 83-89.
- Gedeon, P.C., Thomas, J.R. and Madura, J.D., 2015, Accelerated molecular dynamics and protein conformational change: a theoretical and practical guide using a membrane embedded model neurotransmitter transporter, *Mol. Model. Proteins*, 253-287.

- Ghahremanian, S., Rashidi, M.M., Raeisi, K. and Toghraie, D., 2022, Molecular dynamics simulation approach for discovering potential inhibitors against SARS-CoV-2: A structural review, *J. Mol. Liq.*, 354, 118901.
- Guedes, I.A., de Magalhães, C.S. and Dardenne, L.E., 2014, Receptor–ligand molecular docking, *Biophys. Rev.*, 6, 75-87.
- Hassan, G.S., Abou-Seri, S.M., Kamel, G. and Ali, M.M., 2014, Celecoxib analogs bearing benzofuran moiety as cyclooxygenase-2 inhibitors: design, synthesis and evaluation as potential anti-inflammatory agents, *Eur. J. Med. Chem.*, 76, 482-493.
- Hijos-Mallada, G., Sostres, C. and Gomollón, F., 2022, NSAIDs, gastrointestinal toxicity and inflammatory bowel disease, *Gastroenterol. Hepatol. (Engl Ed.)*, 45(3), 215-222.
- Hollingsworth, S.A. and Dror, R.O., 2018, Molecular dynamics simulation for all, *Neuron*, 99(6), 1129-1143.
- Hospital, A., Goñi, J.R., Orozco, M. and Gelpí, J.L., 2015, Molecular dynamics simulations: advances and applications, *Adv. Appl. Bioinform. Chem.*, 37-47.
- Ju, Z., Li, M., Xu, J., Howell, D.C., Li, Z. and Chen, F.E., 2022, Recent development on COX-2 inhibitors as promising anti-inflammatory agents: The past 10 years, *Acta Pharm. Sin. B.*, 12(6), 2790-2807.
- Levita, J., Rositama, M.R., Alias, N., Khalida, N., Saptarini, N.M. and Megantara, S., 2017, Discovering COX-2 inhibitors from flavonoids and diterpenoids, *J. Appl. Pharm. Sci.*, 7(7), 103-110.
- Limongelli, V., Bonomi, M., Marinelli, L., Gervasio, F.L., Cavalli, A., Novellino, E. and Parrinello, M., 2010, Molecular basis of cyclooxygenase enzymes (COXs) selective inhibition, *Proc. Natl. Acad. Sci.*, 107(12), 5411-5416.
- Macalino, S.J.Y., Gosu, V., Hong, S. and Choi, S., 2015, Role of computer-aided drug design in modern drug discovery, *Arch. Pharmacol. Res.*, 38, 1686-1701.
- Marcoux, J.F., Corley, E.G., Rossen, K., Pye, P., Wu, J., Robbins, M.A., Davies, I.W., Larsen, R.D. and Reider, P.J., 2000, Annulation of ketones with vinamidinium hexafluorophosphate salts: An efficient preparation of trisubstituted pyridines, *Org. Lett.*, 2(15), 2339-2341.
- Martínez, L., 2015, Automatic identification of mobile and rigid substructures in molecular dynamics simulations and fractional structural fluctuation analysis, *PloS one*, 10(3), 0119264.
- McEvoy, L., Carr, D.F. and Pirmohamed, M., 2021, Pharmacogenomics of NSAID-induced upper gastrointestinal toxicity, *Front. Pharmacol.*, 12, 684162.
- Medzhitov, R., 2008, Origin and physiological roles of inflammation, *Nature*, 454(7203), 428-435.
- Micallef, J., Soeiro, T., Jonville-Bera, A.P. and of Pharmacology, F.S., 2020, Non-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection, *Therapies*, 75(4), 355-362.
- Mirzadeh, A., Kobakhidze, G., Vuillemot, R., Jonic, S. and Rouiller, I., 2022, In silico prediction, characterization, docking studies and molecular dynamics

- simulation of human p97 in complex with p37 cofactor, *BMC Mol. Cell Biol.*, 23(1), 39.
- Musfiroh, I., Kartasasmita, R.E., Ibrahim, S., Muchtaridi, M., Hidayat, S. and Ikram, N.K.K., 2023, Stability analysis of the asiatic acid-COX-2 complex using 100 ns molecular dynamic simulations and its selectivity against COX-2 as a potential anti-inflammatory candidate, *Molecules*, 28(9), 3762.
- Pranowo, H.D. dan Hetadi, A.K.R., 2011, *Pengantar Kimia Komputasi*, Penerbit Lubuk Agung, Bandung.
- Razzaghi-Asl, N., Mirzayi, S., Mahnam, K. and Sepehri, S., 2018, Identification of COX-2 inhibitors via structure-based virtual screening and molecular dynamics simulation, *J. Mol. Graph. Model.*, 83, 138-152.
- Ribaldone, D.G., Fagoonee, S., Astegiano, M., De Angelis, C., Smedile, A., Caviglia, G.P., Petrini, E., Greco, A. and Pellicano, R., 2015, Coxib safety in patients with inflammatory bowel diseases: a meta-analysis, *Pain Physician*, 18(6), 599.
- Ricciotti, E. and FitzGerald, G.A., 2011, Prostaglandins and inflammation, *Arterioscler Thromb. Vasc. Biol.*, 31(5), 986-1000.
- Rouzer, C.A. and Marnett, L.J., 2009, Cyclooxygenases: structural and functional insights, *J. Lipid Res.*, 50, S29-S34.
- Sağlık, B.N., Osmaniye, D., Levent, S., Çevik, U.A., Çavuşoğlu, B.K., Özkay, Y. and Kaplancıklı, Z.A., 2021, Design, synthesis and biological assessment of new selective COX-2 inhibitors including methyl sulfonyl moiety, *Eur. J. Med. Chem.*, 209, 112918.
- Seo, S., Choi, J., Park, S. and Ahn, J., 2021, Binding affinity prediction for protein–ligand complex using deep attention mechanism based on intermolecular interactions, *BMC Bioinform.*, 22, 1-15.
- Sihombing, F.W., 2022, Penambatan Molekul dan Simulasi Dinamika Molekul dari Analog Kurkumin sebagai Kandidat Anti-COVID-19 terhadap Protease Utama SARS-CoV-2, *Skripsi*, Departemen Kimia FMIPA UGM, Yogyakarta.
- Smith, F.G., Wade, A.W., Lewis, M.L. and Qi, W., 2012, Cyclooxygenase (COX) inhibitors and the newborn kidney, *Pharmaceuticals*, 5(11), 1160-1176.
- Sohilait, M.R., 2018, Penambatan Molekul, Sintesis dan Uji In Vitro Senyawa Analog Kurkumin sebagai Anti-Inflamasi, *Disertasi*, Departemen Kimia FMIPA UGM, Yogyakarta.
- Sohilait, M.R., Pranowo, H.D. and Haryadi, W., 2017, Molecular docking analysis of curcumin analogues with COX-2, *Bioinform.*, 13(11), 356.
- Tai, F.W.D. and McAlindon, M.E., 2021, Non-steroidal anti-inflammatory drugs and the gastrointestinal tract, *J. Clin. Med.*, 21(2), 131-134.
- Tartaggia, S., Caporale, A., Fontana, F., Stabile, P., Castellin, A. and De Lucchi, O., 2013, A convenient synthesis of the key intermediate of selective COX-2 inhibitor Etoricoxib, *RSC Adv.*, 3(40), 18544-18549.
- Tjandrawinata, R.R., Setiawati, A., Nofiarny, D., Susanto, L.W. and Setiawati, E., 2018, Pharmacokinetic equivalence study of nonsteroidal anti-inflammatory drug etoricoxib, *Clin. Pharmacol.: Adv. Appl.*, 43-51.

- Torres, P.H., Sodero, A.C., Jofily, P. and Silva-Jr, F.P., 2019, Key topics in molecular docking for drug design, *Int. J. Mol. Sci.*, 20(18), 4574.
- van de Laar, M.A., Schöfl, R., Prevoo, M. and Jastorff, J., 2023, Predictive value of gastrointestinal symptoms and patient risk factors for NSAID-associated gastrointestinal ulcers defined by endoscopy? Insights from a pooled analysis of two naproxen clinical trials, *PloS one*, 18(4), 0284358.
- Vidal-Limon, A., Aguilar-Toalá, J.E. and Liceaga, A.M., 2022, Integration of molecular docking analysis and molecular dynamics simulations for studying food proteins and bioactive peptides, *J. Agric. Food Chem.*, 70(4), 934-943.